4.5 Article

Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study

Journal

JAMA NEUROLOGY
Volume 75, Issue 3, Pages 279-286

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2017.3949

Keywords

-

Funding

  1. Eisai Ltd
  2. UCB Pharma
  3. Lundbeck
  4. National Health and Medical Research Council of Australia
  5. Australian Research Council
  6. National Heart Foundation of Australia
  7. Pfizer
  8. AbbVie
  9. Sanofi
  10. AstraZeneca
  11. GlaxoSmithKline
  12. Amgen
  13. US National Institutes of Health
  14. Hong Kong Research Grants Council
  15. Innovation and Technology Fund
  16. Health and Health Services Research Fund
  17. Health and Medical Research Fund
  18. Eisai
  19. Johnson Johnson

Ask authors/readers for more resources

IMPORTANCE A study published in 2000 showed that more than one-third of adults with epilepsy have inadequate control of seizures with antiepileptic drugs (AEDs). This study evaluates overall treatment outcomes in light of the introduction of more than 1 dozen new AEDs in the past 2 decades. OBJECTIVE To assess long-term treatment outcome in patients with newly diagnosed and treated epilepsy. DESIGN, SETTING, AND PARTICIPANTS This longitudinal observational cohort study was conducted at the Epilepsy Unit of the Western Infirmary in Glasgow, Scotland. A total of 1795 individuals who were newly treated for epilepsy with AEDs between July 1, 1982, and October 31, 2012, were included in this analysis. All patients were followed up for a minimum of 2 years (until October 31, 2014) or until death, whichever came sooner. Data analysis was completed between March 2015 and May 2016. EXPOSURES Treatment with antiepileptic drugs for patients newly diagnosed with epilepsy. MAIN OUTCOMES AND MEASURES Seizure control was assessed at the end of the study period. Probability of achieving 1-year seizure freedom was estimated for each AED regimen prescribed. Multivariable models assessed the associations between risk factors and AED treatment outcome after adjustments were made for demographic and clinical characteristics. RESULTS Of the 1795 included patients, 964 (53.7%) were male; the median age was 33 years (range, 9-93 years). At the end of the study period, 1144 patients (63.7%) had been seizure free for the previous year or longer. Among those achieving 1-year seizure freedom, 993 (86.8%) were taking monotherapy and 1028 (89.9%) had achieved seizure control with the first or second AED regimens. Of the total patient pool, 906 (50.5%) remained seizure free for 1 year or longer with the initial AED. If this AED failed, the second and third regimens provided an additional 11.6% and 4.4% likelihoods of seizure freedom, respectively. Only 2.12% of patients attained optimal seizure control with subsequent AEDs. Epilepsy that was not successfully controlled with the first AED had 1.73 times greater odds of not responding to treatment for each subsequent medication regimen (odds ratio, 1.73; 95% CI, 1.56-1.91; P < .001). CONCLUSIONS AND RELEVANCE Despite the availability of many new AEDs with differing mechanisms of action, overall outcomes in newly diagnosed epilepsy have not improved. Most patients who attain control do so with the first or second AED. The probability of achieving seizure freedom diminishes substantially with each subsequent AED regimen tried. More than one-third of patients experience epilepsy that remains uncontrolled.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available